Miraqules will showcase its blood clotting technology at TechCrunch Disrupt 2025

Bengaluru-based startup Miraqules has developed an innovative nanotechnology powder that mimics blood clotting proteins, enabling rapid blood absorption and clotting within one to two minutes at room temperature. The technology emerged accidentally during biomedical research and was refined into a product that provides instant feedback by stopping bleeding quickly when applied. Miraqules has secured 11 patents across seven countries, including India, the U.S., and Israel, and is currently piloting its product in an Indian trauma care center. The company anticipates regulatory approval in India soon and expects U.S. FDA clearance by 2026. Despite raising less than $700,000 primarily through grants, Miraqules has attracted interest from multiple hospital chains in India and the Israeli Defense Forces. The founders engaged early with the U.S. FDA through pre-submission feedback to streamline the approval process. Miraqules will showcase its blood clotting technology as a Top 20 finalist at TechCrunch Disrupt 2025, held October